{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:22:25Z","timestamp":1793906545743,"version":"4.8.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1136\/ard-2022-222549","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T13:25:20Z","timestamp":1660656320000},"page":"1695-1703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-\u03b1"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-6528","authenticated-orcid":false,"given":"Alexis","family":"Mathian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0475-1218","authenticated-orcid":false,"given":"Paul","family":"Breillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-3203","authenticated-orcid":false,"given":"Karim","family":"Dorgham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Charre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Lhote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Quentric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Moyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice-Andr\u00e9e","family":"Mariaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Mouries-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Mellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Haroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Cohen-Aubart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5993-687X","authenticated-orcid":false,"given":"Delphine","family":"Sterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00ebl","family":"Zahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Le Voyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Bizien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheline","family":"Pha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Hi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Chasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Yssel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Miyara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Charneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Ghillani-Dalbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Laurent","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2097-9677","authenticated-orcid":false,"given":"Guy","family":"Gorochov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222549_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1136\/ard-2022-222549_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4348","article-title":"X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19","volume":"6","author":"Asano","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1136\/ard-2022-222549_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1136\/ard-2022-222549_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1136\/ard-2022-222549_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh2624","article-title":"Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19","volume":"13","author":"van der Wijst","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1136\/ard-2022-222549_bib6","article-title":"Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs","volume":"218","author":"Lopez","year":"2021","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2022-222549_bib7","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202486","article-title":"Auto-Antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2022-222549_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000336","article-title":"Type I interferons in host defence and inflammatory diseases","volume":"6","author":"Crow","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-222549_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/107999003321532475","article-title":"Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia","volume":"23","author":"Slavikova","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"10.1136\/ard-2022-222549_bib10","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/art.30399","article-title":"Association of endogenous anti-interferon-\u03b1 autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus","volume":"63","author":"Morimoto","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222549_bib11","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/art.39607","article-title":"Distinct functions of autoantibodies against interferon in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222549_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00269199","article-title":"Presence of interferon and anti-interferon in patients with systemic lupus erythematosus","volume":"8","author":"von Wussow","year":"1988","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-222549_bib13","article-title":"Correspondence on \u2018Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine\u2018","author":"Gupta","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222549_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222549_bib17","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League against Rheumatism\/American College of rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222549_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/251543a0","article-title":"Pronounced antiviral activity of human interferon on bovine and porcine cells","volume":"251","author":"Gresser","year":"1974","journal-title":"Nature"},{"key":"10.1136\/ard-2022-222549_bib19","first-page":"267","article-title":"Early intrathecal synthesis of interferon in herpes encephalitis","volume":"31","author":"Lebon","year":"1979","journal-title":"Biomedicine"},{"key":"10.1136\/ard-2022-222549_bib20","first-page":"37","article-title":"[Production of human type I interferon by lymphocytes in contact with cells infected by herpesvirus and fixed with glutaraldehyde]","volume":"290","author":"Lebon","year":"1980","journal-title":"C R Seances Acad Sci D"},{"key":"10.1136\/ard-2022-222549_bib21","first-page":"509","article-title":"FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus","volume":"10","author":"Batteux","year":"1999","journal-title":"Eur Cytokine Netw"},{"key":"10.1136\/ard-2022-222549_bib22","first-page":"1135","article-title":"Synth\u00e8se d'interf\u00e9ron Au cours des enc\u00e9phalites herp\u00e8tiques de l'Adulte","volume":"10","author":"Vezinet","year":"1981","journal-title":"Nouv Presse M\u00e9d"},{"key":"10.1136\/ard-2022-222549_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0022-510X(88)90125-6","article-title":"Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy","volume":"84","author":"Lebon","year":"1988","journal-title":"J Neurol Sci"},{"key":"10.1136\/ard-2022-222549_bib24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/infdis\/150.5.707","article-title":"Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease","volume":"150","author":"Pozzetto","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1136\/ard-2022-222549_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd2223","article-title":"Iga dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1136\/ard-2022-222549_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.32614\/RJ-2016-042","article-title":"easyROC: an interactive web-tool for ROC curve analysis using R language environment","volume":"8","author":"Goksuluk","year":"2016","journal-title":"R J"},{"key":"10.1136\/ard-2022-222549_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2021.09.002","article-title":"Human genetic and immunological dissection of papillomavirus-driven diseases: new insights into their pathogenesis","volume":"51","author":"B\u00e9ziat","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1136\/ard-2022-222549_bib28","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200413119","article-title":"The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies","volume":"119","author":"Manry","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2022-222549_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1074-7613(03)00208-5","article-title":"Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6","volume":"19","author":"Jego","year":"2003","journal-title":"Immunity"},{"key":"10.1136\/ard-2022-222549_bib30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/annrheumdis-2021-221097","article-title":"BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus","volume":"81","author":"Moyon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222549_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.129.1.1","article-title":"Antibodies to alpha-interferon in a patient with systemic lupus erythematosus","volume":"129","author":"Panem","year":"1982","journal-title":"J Immunol"},{"key":"10.1136\/ard-2022-222549_bib32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/intimm\/dxg088","article-title":"Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor","volume":"15","author":"Shiono","year":"2003","journal-title":"Int Immunol"},{"key":"10.1136\/ard-2022-222549_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2004.03.013","article-title":"Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. epitope mapping","volume":"23","author":"Bello-Rivero","year":"2004","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2022-222549_bib34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2249.2003.02113.x","article-title":"Anti-Cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and\/or myasthenia gravis","volume":"132","author":"Meager","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard-2022-222549_bib35","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1371\/journal.pmed.0030292","article-title":"Anti-Interferon auto-antibodies in autoimmune polyendocrinopathy syndrome type 1","volume":"3","author":"Levin","year":"2006","journal-title":"PLoS Med"},{"key":"10.1136\/ard-2022-222549_bib36","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cell.2016.06.024","article-title":"AIRE-Deficient patients harbor unique high-affinity Disease-Ameliorating autoantibodies","volume":"166","author":"Meyer","year":"2016","journal-title":"Cell"},{"key":"10.1136\/ard-2022-222549_bib37","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","article-title":"Anti-Interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1","volume":"3","author":"Meager","year":"2006","journal-title":"PLoS Med"},{"key":"10.1136\/ard-2022-222549_bib38","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1172\/JCI80477","article-title":"Broad-Spectrum antibodies against self-antigens and cytokines in RAG deficiency","volume":"125","author":"Walter","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2022-222549_bib39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fimmu.2018.00544","article-title":"Neutralizing anti-cytokine autoantibodies against interferon-\u03b1 in Immunodysregulation polyendocrinopathy enteropathy X-linked","volume":"9","author":"Rosenberg","year":"2018","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2022-222549_bib40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-222549_bib41","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(81)91460-4","article-title":"Patient with circulating antibodies to alpha-interferon","volume":"2","author":"Mogensen","year":"1981","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222549_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000464","article-title":"Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials","volume":"8","author":"Tummala","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-222549_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001709","article-title":"Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease","volume":"20","author":"Busnadiego","year":"2022","journal-title":"PLoS Biol"},{"key":"10.1136\/ard-2022-222549_bib44","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/289496a0","article-title":"Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon","volume":"289","author":"Vallbracht","year":"1981","journal-title":"Nature"},{"key":"10.1136\/ard-2022-222549_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0166-3542(94)90070-1","article-title":"Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy","volume":"24","author":"Antonelli","year":"1994","journal-title":"Antiviral Res"},{"key":"10.1136\/ard-2022-222549_bib46","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1212\/WNL.50.5.1266","article-title":"Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. multiple sclerosis Collaborative Research Group (MSCRG)","volume":"50","author":"Rudick","year":"1998","journal-title":"Neurology"},{"key":"10.1136\/ard-2022-222549_bib47","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222549_bib48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-222549_bib49","author":"761123Orig1s000MultidisciplineR"},{"key":"10.1136\/ard-2022-222549_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102598","article-title":"COVID-19 convalescent plasma composition and immunological effects in severe patients","volume":"118","author":"Acosta-Ampudia","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1136\/ard-2022-222549_bib51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10875-021-01203-3","article-title":"Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital","volume":"42","author":"Chauvineau-Grenier","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1136\/ard-2022-222549_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1327","article-title":"Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients","volume":"10","author":"Goncalves","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1136\/ard-2022-222549_bib53","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00134-021-06392-4","article-title":"Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients","volume":"47","author":"Koning","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1136\/ard-2022-222549_bib54","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s10875-021-01136-x","article-title":"Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona","volume":"41","author":"Solanich","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1136\/ard-2022-222549_bib55","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s10875-021-01036-0","article-title":"Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain","volume":"41","author":"Troya","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1136\/ard-2022-222549_bib56","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10875-021-01060-0","article-title":"Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma","volume":"41","author":"Vazquez","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1136\/ard-2022-222549_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","article-title":"Diverse functional autoantibodies in patients with COVID-19","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1136\/ard-2022-222549_bib58","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/imcb.12495","article-title":"Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19","volume":"99","author":"Abers","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"10.1136\/ard-2022-222549_bib59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s10875-021-01168-3","article-title":"Interferon-\u03b12 auto-antibodies in convalescent plasma therapy for COVID-19","volume":"42","author":"Raadsen","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1136\/ard-2022-222549_bib60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1136\/ard-2022-222549_bib61","article-title":"Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs","author":"Bastard","year":"2022","journal-title":"Sci Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724087363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724087363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T03:28:41Z","timestamp":1736047721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724087363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0003496724087363"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222549","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-\u03b1","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}